<DOC>
	<DOCNO>NCT01689519</DOCNO>
	<brief_summary>To evaluate efficacy vemurafenib combination cobimetinib ( GDC-0973 ) , compare vemurafenib placebo , previously untreated BRAF V600 mutation-positive patient unresectable locally advanced metastatic melanoma , measure progression-free survival ( PFS ) , assess study site investigator .</brief_summary>
	<brief_title>A Phase III Study Comparing Vemurafenib v Vemurafenib Plus Cobimetinib ( GDC-0973 ) Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients histologically confirm melanoma , either unresectable stage IIIc stage IV metastatic melanoma , define American Joint Committee Cancer 7th edition . Unresectability stage IIIc disease must confirmation surgical oncologist . Patients must naïve treatment locally advance unresectable metastatic disease ( ie , prior systemic anticancer therapy advance disease ; stage IIIc IV ) . Prior adjuvant immunotherapy ( include ipilimumab ) allow . Documentation BRAF V600 mutationpositive status melanoma tumor tissue ( archival newly obtain tumor sample ) use cobas 4800 BRAF V600 mutation test . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 . Eastern Clinical Oncology Group performance status 0 1 . Consent provide archival biomarker analysis . Consent undergo tumor biopsy biomarker analysis . Life expectancy ≥ 12 week . Adequate hematologic end organ function . History prior rapidly accelerate fibrosarcoma ( RAF ) mitogenactivated protein kinase ( MEK ) pathway inhibitor treatment . Palliative radiotherapy within 14 day prior first dose study treatment . Major surgery traumatic injury within 14 day prior first dose study treatment . Active malignancy melanoma could potentially interfere interpretation efficacy measure . Patients previous malignancy within past 3 year exclude except patient resect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) skin , melanoma insitu , carcinoma insitu cervix , carcinoma insitu breast . History evidence retinal pathology ophthalmological examination consider risk factor neurosensory retinal detachment , retinal vein occlusion ( RVO ) , neovascular macular degeneration . Uncontrolled glaucoma intraocular pressure . Serum cholesterol ≥ Grade 2 . Hypertriglyceridemia ≥ Grade 2 . Hyperglycemia ( fast ) ≥ Grade 2 . History clinically significant cardiac dysfunction . Patients active central nervous system ( CNS ) lesion ( include carcinomatous meningitis ) exclude . However , patient eligible : 1 . All know CNS lesion treat stereotactic therapy surgery , AND 2 . There evidence clinical radiographic disease progression CNS ≥ 3 week radiotherapy surgery . Current severe , uncontrolled systemic disease . History malabsorption condition would interfere absorption study drug . Pregnant , lactating , breast feeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Zelboraf</keyword>
	<keyword>vemurafenib</keyword>
	<keyword>RG7204</keyword>
	<keyword>PLX4032</keyword>
	<keyword>Genentech MEK inhibitor</keyword>
	<keyword>Genentech BRAF inhibitor</keyword>
	<keyword>Roche MEK inhibitor</keyword>
	<keyword>Roche BRAF inhibitor</keyword>
	<keyword>RO5185426</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>BRAF positive melanoma</keyword>
	<keyword>BRAF mutant melanoma</keyword>
	<keyword>advanced melanoma</keyword>
	<keyword>Genentech RAF inhibitor</keyword>
	<keyword>Roche RAF inhibitor</keyword>
	<keyword>BRAF V600E kinase inhibitor</keyword>
	<keyword>Oncogenic BRAF inhibitor</keyword>
	<keyword>BRAF kinase inhibitor</keyword>
	<keyword>GDC-0973</keyword>
	<keyword>XL518</keyword>
	<keyword>melanoma</keyword>
</DOC>